港股异动 | 荣昌生物(09995)绩后高开近4% 中期净亏损约4.5亿元 同比减少42.4%

Core Viewpoint - Rongchang Biologics (09995) reported a strong performance for the first half of 2025, with significant revenue growth driven by the commercialization of its immunotherapy products [1] Financial Performance - Product sales and R&D service revenue reached 1.092 billion yuan, an increase of 47.6% year-on-year [1] - R&D expenses decreased by 19.7% to 647 million yuan [1] - The net loss was approximately 450 million yuan, a reduction of 42.4% compared to the previous year [1] - Earnings per share reported a loss of 0.83 yuan [1] Revenue Drivers - The revenue increase was primarily attributed to the strong sales of the company's immunotherapy product, Tai Tasi, and the oncology product, Vidisizumab [1]